In today's world, RWJ-394674 is a topic that is constantly evolving and that arouses great interest in society. Whether due to its historical relevance, its impact on popular culture or its influence on everyday life, RWJ-394674 has managed to capture the attention of people of all ages and backgrounds. In this article, we will explore in detail the different aspects related to RWJ-394674, from its origin to its present day, analyzing its importance and impact on various aspects of modern life. Additionally, we will examine the role RWJ-394674 plays in today's society and how it has influenced the way we think and act. Through in-depth and comprehensive analysis, we will be in a position to better understand the importance of RWJ-394674 and its impact on the world around us.
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C33H38N2O |
Molar mass | 478.680 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
RWJ-394674 is a drug that is used in scientific research. It is a potent, orally active analgesic drug that produces little respiratory depression. RWJ-394674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24 nM at δ and 72 nM at μ. However once inside the body, RWJ-394674 is dealkylated to its monodesethyl metabolite RWJ-413216, which is a potent agonist at the μ-opioid receptor and has less affinity for δ (Ki of 0.26 nM at μ, 46.7 nM at δ). The effect of RWJ-394674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side-effect being sedation.[1]